ESMO 2023 - Small Cell Lung Cancer

Based on improvements in survival outcomes with a PD-1/PD-L1 inhibitor in combination with chemotherapy in patients with extensive-stage small cell lung cancer (SCLC), a nonrandomized, single-center, phase 2 study (LungMate-005; NCT04539977) was conducted to explore the clinical safety and efficacy of neoadjuvant PD-L1 inhibitor TQB2450 plus chemotherapy induction therapy followed by surgery or radiotherapy in patients with limited-stage small-cell lung cancer (LS-SCLC). Read More ›

Atezolizumab plus carboplatin/etoposide is indicated for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) based on results of the pivotal phase 3 IMpower133 trial. Read More ›

The majority of patients with small cell lung cancer (SCLC) present with extensive-stage disease, which is associated with poor prognosis. Read More ›

Phase 1 results of the prospective, open-label, uncontrolled, multicenter, phase 1/2 LUPER study (NCT04358237) indicated that the lurbinectedin plus the anti–PD-1 pembrolizumab combination regimen showed promising antitumor activity with a manageable safety profile in patients with relapsed small cell lung cancer (SCLC) and established the recommended phase 2 dose (RP2D) of lurbinectedin + pembrolizumab. Read More ›

Extensive-stage small cell lung cancer (ES-SCLC) is often treated with a combination of immunotherapy and chemotherapy; however, limited treatment options are available following progression on this combination regimen, underscoring the need for novel therapies in the second-line setting. Read More ›

The randomized, placebo-controlled, phase 3 EXTENTORCH trial (NCT04012606) assessed the clinical efficacy and safety of the anti–PD-1 antibody toripalimab in combination with etoposide plus platinum-based chemotherapy for the first-line treatment of patients with extended-stage SCLC (ES-SCLC); initial results of this study, presented at the 2023 ESMO annual meeting, are summarized here. Read More ›

New immunotherapeutic approaches are being investigated in small cell lung cancer (SCLC). Tarlatamab is a bispecific T-cell engager that binds to both delta-like ligand 3 (DLL3) on SCLC cells and CD3 on T cells to elicit T-cell–mediated tumor lysis. Read More ›